The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
 
Mody Amin
No Relationships to Disclose
 
Alex Niu
No Relationships to Disclose
 
Kristopher Attwood
No Relationships to Disclose
 
Anthony George
No Relationships to Disclose
 
Farhan Azad
No Relationships to Disclose
 
Jerry Wong
No Relationships to Disclose
 
Grant Schofield
No Relationships to Disclose
 
Dorothy C. Pan
No Relationships to Disclose
 
Sheila N. J. Sait
No Relationships to Disclose
 
Anne Marie W. Block
No Relationships to Disclose
 
Eugene Przespolewski
No Relationships to Disclose
 
Carolyn Connors
No Relationships to Disclose
 
Joseph Demarco
No Relationships to Disclose
 
Keryn Gauch
No Relationships to Disclose
 
Nikolina Gjorgievski
No Relationships to Disclose
 
Michael Johnson
No Relationships to Disclose
 
Linda Manth
No Relationships to Disclose
 
Kenneth McWhite
No Relationships to Disclose
 
Matthew Joseph Cortese
No Relationships to Disclose
 
Francisco J. Hernandez-Ilizaliturri
Consulting or Advisory Role - Abbvie; BeiGene; Epizyme; Kite/Gilead; Morphosys; Novartis; Pharmacyclics; Seagen